Pharmamarketeer
onderzoek

Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

14 maart 2019
InPharm.com

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials.

The study found that 44% of patients with severe to moderate ulcerative colitis who took 90mg of Stelara every eight weeks and 38% of those who took 90mg every 12 weeks achieved clinical remission as defined by the Mayo score, at week 44 compared to 24 percent of patients who received placebo.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)